Verge Genomics

Verge Genomics

Verge Genomics is a company focused on the discovery and development of drugs for the treatment of neurodegenerative diseases with the use of machine learning and computational genomics.

Verge Genomics is a company that develops a drug discovery platform for neurodegenerative diseases. It was founded in 2015 by Alice Zhang and Jason Chen. Verge Genomics has received funding from OS Fund, WuXi AppTec, and ALS Investment Fund. The company is headquartered in San Francisco, California, United States.

Products and services

Verge Genomics's computational biology and artificial intelligence platform is able to generate novel drug compounds to target genes involved in neurodegenerative diseases. The platform is designed to construct new therapeutics for diseases that are caused by multiple gene anomalies. The company uses datasets collected from human tissue samples of patients with diseases such as Parkinson's and amyotrophic lateral sclerosis (ALS). Several new therapeutics for ALS developed by Verge Genomics have passed preclinical trials.

Timeline

July 2018

Verge Genomics raises a $32,000,000 series A round from Agent Capital, ALS Investment Fund, DFJ, OS Fund and WuXi AppTec Corporate Venture fund.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Verge Genomics funding round, July 2018
Series A round
32,000,000
July 2018
DFJ
WuXi AppTec Corporate Venture fund
ALS Investment Fund
Agent Capital
OS Fund
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alice Zhang

Founder

Andrew Jiang

Investor

Dave Morin

Investor

Henry McNamara

Investor

Jason Chen

Founder

Kevin Colleran

Investor

Kimberly Vogel

Investor

Lucia Huang

Employee

Marlo Miller

Employee

Shannon Stone

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.